Katharina Schutte
Overview
Explore the profile of Katharina Schutte including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
26
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gunther M, Hentschel L, Schuler M, Muller T, Schutte K, Ko Y, et al.
BMC Cancer
. 2023 Jul;
23(1):629.
PMID: 37407982
Background: To include the patient perspective in the assessment of adverse events in oncology, a patient-reported outcomes (PRO) version of the Common Terminology Criteria for Adverse Events (CTCAE) was developed...
2.
Schutte K, Trautmann-Grill K
Schmerz
. 2022 Oct;
36(6):447-457.
PMID: 36260170
Paraneoplastic syndromes (PS) are rare disorders with often complex clinical manifestations that occur in association with a tumor without being triggered by direct tumor invasion or compression. They arise from...
3.
Hahn W, Schutte K, Schultz K, Wolkenhauer O, Sedlmayr M, Schuler U, et al.
J Pers Med
. 2022 Aug;
12(8).
PMID: 36013227
AI model development for synthetic data generation to improve Machine Learning (ML) methodologies is an integral part of research in Computer Science and is currently being transferred to related medical...
4.
Hentschel L, Wellesen A, Krause L, von Havranek M, Kramer M, Hornemann B, et al.
BMC Palliat Care
. 2022 May;
21(1):62.
PMID: 35501763
Background: Although the majority of German patients in a palliative state prefer to die at home, the actual place of death is most often a hospital. Unplanned hospital readmissions (UHA)...
5.
Folprecht G, Trautmann K, Stein A, Huebner G, Stahl M, Kasper S, et al.
Br J Cancer
. 2020 Nov;
124(4):721-727.
PMID: 33235314
Background: Patients with carcinoma of unknown primary (CUP) have a dismal prognosis, even when treated with multi-agent chemotherapy. We hypothesised that adding the epidermal growth-factor receptor (EGFR) inhibitor cetuximab to...
6.
Folprecht G, Hamann S, Schutte K, Trarbach T, Stoehlmacher-Williams J, Ehninger G
BMC Cancer
. 2014 Jul;
14:521.
PMID: 25038824
Background: The FOLFOXIRI regimen (irinotecan, oxaliplatin, fluorouracil [5-FU] and folinic acid [FA]) increased the response rate and overall survival compared to FOLFIRI in patients with metastatic colorectal cancer (mCRC). Adding...